Time and Diffusion Lesion Size in Major Anterior Circulation Ischemic Strokes

Background and Purpose— Major anterior circulation ischemic strokes caused by occlusion of the distal internal carotid artery or proximal middle cerebral artery or both account for about one third of ischemic strokes with mostly poor outcomes. These strokes are treatable by intravenous tissue-type plasminogen activator and endovascular methods. However, dynamics of infarct growth in these strokes are poorly documented. The purpose was to help understand infarct growth dynamics by measuring acute infarct size with diffusion-weighted imaging (DWI) at known times after stroke onset in patients with documented internal carotid artery/middle cerebral artery occlusions. Methods— Retrospectively, we included 47 consecutive patients with documented internal carotid artery/middle cerebral artery occlusions who underwent DWI within 30 hours of stroke onset. Prospectively, 139 patients were identified using the same inclusion criteria. DWI lesion volumes were measured and correlated to time since stroke onset. Perfusion data were reviewed in those who underwent perfusion imaging. Results— Acute infarct volumes ranged from 0.41 to 318.3 mL. Infarct size and time did not correlate (R2=0.001). The majority of patients had DWI lesions that were <25% the territory at risk (<70 mL) whether they were imaged <8 or >8 hours after stroke onset. DWI lesions corresponded to areas of greatly reduced perfusion. Conclusions— Poor correlation between infarct volume and time after stroke onset suggests that there are factors more powerful than time in determining infarct size within the first 30 hours. The observations suggest that highly variable cerebral perfusion via the collateral circulation may primarily determine infarct growth dynamics. If verified, clinical implications include the possibility of treating many patients outside traditional time windows.

[1]  G. Zaharchuk,et al.  Hypoperfusion Intensity Ratio Predicts Infarct Progression and Functional Outcome in the DEFUSE 2 Cohort , 2014, Stroke.

[2]  R. Gonzalez,et al.  Good Outcome Rate of 35% in IV-tPA–Treated Patients With Computed Tomography Angiography Confirmed Severe Anterior Circulation Occlusive Stroke , 2013, Stroke.

[3]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[4]  F. Nicoli,et al.  Perfusion-Weighted Imaging–Derived Collateral Flow Index is a Predictor of MCA M1 Recanalization after IV Thrombolysis , 2013, American Journal of Neuroradiology.

[5]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[6]  L. Schwamm,et al.  Rapid identification of a major diffusion/perfusion mismatch in distal internal carotid artery or middle cerebral artery ischemic stroke , 2012, BMC Neurology.

[7]  Manabu Inoue,et al.  MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study , 2012, The Lancet Neurology.

[8]  Z. Chaudhry,et al.  Infarct Volume Is a Pivotal Biomarker After Intra-Arterial Stroke Therapy , 2012, Stroke.

[9]  Wade S. Smith,et al.  Effect of Time to Reperfusion on Clinical Outcome of Anterior Circulation Strokes Treated With Thrombectomy: Pooled Analysis of the MERCI and Multi MERCI Trials , 2011, Stroke.

[10]  Geoffrey A. Donnan,et al.  Refining the Definition of the Malignant Profile: Insights From the DEFUSE-EPITHET Pooled Data Set , 2011, Stroke.

[11]  A. Abou-Chebl,et al.  Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients , 2010, Stroke.

[12]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[13]  A. Sorensen,et al.  Stability of large diffusion/perfusion mismatch in anterior circulation strokes for 4 or more hours , 2010, BMC neurology.

[14]  J. Broderick,et al.  Good clinical outcome after ischemic stroke with successful revascularization is time-dependent , 2009, Neurology.

[15]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[16]  R. Gonzalez,et al.  MRI-Based Selection for Intra-Arterial Stroke Therapy: Value of Pretreatment Diffusion-Weighted Imaging Lesion Volume in Selecting Patients With Acute Stroke Who Will Benefit From Early Recanalization , 2009, Stroke.

[17]  W. Copen,et al.  Existence of the diffusion-perfusion mismatch within 24 hours after onset of acute stroke: dependence on proximal arterial occlusion. , 2009, Radiology.

[18]  J. Alger,et al.  Determinants of the distribution and severity of hypoperfusion in patients with ischemic stroke , 2008, Neurology.

[19]  Joseph P Broderick,et al.  National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate , 2008, Stroke.

[20]  F Viñuela,et al.  Impact of collateral flow on tissue fate in acute ischaemic stroke , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  Jan van Gijn,et al.  Clinical practice. Acute ischemic stroke. , 2007, The New England journal of medicine.

[22]  P. Kaňovský,et al.  Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis , 2006, Neuroradiology.

[23]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[24]  R. Gonzalez,et al.  Imaging-guided acute ischemic stroke therapy: From "time is brain" to "physiology is brain". , 2006, AJNR. American journal of neuroradiology.

[25]  J. Saver Time Is Brain—Quantified , 2006, Stroke.

[26]  D. Liebeskind Collaterals in acute stroke: beyond the clot. , 2005, Neuroimaging clinics of North America.

[27]  G. Christoforidis,et al.  Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. , 2005, AJNR. American journal of neuroradiology.

[28]  Timothy Q. Duong,et al.  Perfusion and diffusion imaging in acute focal cerebral ischemia: Temporal vs. spatial resolution , 2005, Brain Research.

[29]  J. Martí-Fàbregas,et al.  Reasons for exclusion from thrombolytic therapy following acute ischemic stroke , 2005, Neurology.

[30]  G Schlaug,et al.  Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility , 2001, Neurology.

[31]  T. Neumann-Haefelin,et al.  Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. , 2000, Stroke.

[32]  A. Furlan,et al.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.

[33]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[34]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[35]  P Trouillas,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.

[36]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.